Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · Real-Time Price · USD
1.770
+0.020 (1.14%)
Dec 20, 2024, 4:00 PM EST - Market closed
Iterum Therapeutics Employees
Iterum Therapeutics had 14 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,182,429
Market Cap
48.70M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Xtant Medical Holdings | 215 |
Cytosorbents | 186 |
Fortress Biotech | 186 |
Prelude Therapeutics | 128 |
Inovio Pharmaceuticals | 122 |
Shattuck Labs | 75 |
iCAD, Inc. | 69 |
Kezar Life Sciences | 58 |
ITRM News
- 4 weeks ago - Iterum Therapeutics Regains Full Nasdaq Compliance - GlobeNewsWire
- 5 weeks ago - Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Iterum Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript) - Seeking Alpha
- 7 weeks ago - Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - PRNewsWire
- 2 months ago - Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - GlobeNewsWire
- 2 months ago - US FDA approves Iterum's treatment for urinary infection - Reuters
- 2 months ago - Iterum Therapeutics to Present Data at IDWeek 2024 - GlobeNewsWire